<DOC>
	<DOCNO>NCT00671125</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Ramelteon , daily ( QD ) , treatment chronic insomnia use polysomnography subjective measure sleep</brief_summary>
	<brief_title>Study Efficacy Ramelteon Adults With Chronic Insomnia</brief_title>
	<detailed_description>Insomnia characterize difficulty initiate maintain sleep nonrestorative non-refreshing sleep . Transient insomnia affect approximately one-third one-half US population , base result 2 survey representative sample adult US population conduct Gallup Organization respondent ask `` ever difficulty sleep . '' Based report `` regular '' `` frequent '' sleep difficulty , result study suggest approximately one-tenth US population experience chronic insomnia . The ideal treatment insomnia would reduce latency onset sleep increase total sleep time , without negative impact sleep architecture without safety concern next-day effect . Ramelteon selective melatonin-1 receptor agonist global development Takeda Chemical Industries , Ltd. , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders . This study determine safety efficacy 35-day treatment chronic insomnia Ramelteon use polysomnography subjective measure sleep . Participation study anticipate 2 month .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Females childbearing potential must postmenopausal 1 year history hysterectomy and/or oophorectomy . Primary insomnia define DSMIVTRTM least 3 month define subjective sleep latency ( sSL ) great equal 30 minute , subjective total sleep time ( sTST ) less equal 6.5 hour per night , daytime complaint ( ) associate disturbed sleep . Mean latency great equal 20 minute 2 consecutive screen night neither night le 15 minute . Also , mean 60 minute wake time 480 minute bed across two night night le 45 minute screen night neither night le 15 minute . Also , mean 60 minute wake time 480 minute bed across two night night le 45 minute . Habitual bedtime 8:30 p.m. 12:00 a.m . Body mass index 18 34 , inclusive . Exclusion Criteria Known hypersensitivity Ramelteon related compound , include melatonin . Previously participate study involve Ramelteon . Participated investigational study and/or take investigational drug within 30 day five halflives prior first night singleblind study medication , whichever longer . Sleep schedule change require employment ( e.g . shift worker ) within three month prior first night singleblind study medication , fly across great three time zone within seven day prior screen . Participated weight loss program substantially alter exercise routine within 30 day prior first night single blind study medication . Ever history seizure , sleep apnea , chronic obstructive pulmonary disease , schizophrenia , bipolar disorder , mental retardation , cognitive disorder . History psychiatric disorder ( include anxiety depression ) within past 12 month . History drug addiction drug abuse within past 12 month . History alcohol abuse within past 12 month , define Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised and/or regularly consume 4 alcoholic drink per day . Current significant neurological , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematologic , metabolic disease , unless currently control stable protocolallowed medication 30 day prior first night singleblind study medication . Uses tobacco product nightly awakening . Used melatonin , drug supplement know affect sleep/wake function within 1 week ( 5 half life drug , whichever long ) prior first day singleblind study medication . Used central nervous system medication within 1 week ( 5 half life drug , whichever long ) prior first day singleblind study medication . These medication must use treat psychiatric disorder . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram , clinical laboratory test , determine investigator . Positive hepatitis panel . Positive urine drug screen include alcohol screen positive breathalyzer test checkin . Apnea hypopnea index ( per hour sleep ) great 10 see polysomnogram , first night polysomnogram screening . Periodic leg movement arousal index ( per hour sleep ) great 10 see polysomnogram , first night polysomnogram screening . Any additional condition ( ) Investigator 's opinion would : affect sleep/wake function prohibit subject complete study best interest subject . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication , include : Anxiolytics Hypnotics Antidepressants Anticonvulsants Sedating H1 antihistamine Systemic steroid Respiratory stimulant ( eg , theophylline ) Decongestants Overthecounter prescription stimulant Overthecounter prescription diet aids Central nervous system active drug ( include herbal preparation central nervous system effect ) Narcotic analgesic All beta blocker Melatonin St. John 's Wort Kavakava Gingko biloba</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Sleep Disorder</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>